: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:2055–2063.PubMedCrossRef 16. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, et al.: Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401

study. Ann Oncol 2004, 15:79–87.PubMedCrossRef 17. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, LY2109761 purchase Osborne CK: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994, 12:2078–2085.PubMed 18. Penault-Llorca F, Andre F, Sagan

C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, et al.: Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2809–2815.PubMedCrossRef 19. Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, Rosty C, Nos C, Campana F, Klijanienko J, et al.: Proliferation markers predictive High Content Screening of the pathological response learn more and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004, 40:1502–1508.PubMedCrossRef

20. Xu L, Liu YH, Ye JM, Zhao JX, Duan XN, Zhang LB, Zhang H, Wang YH: Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer. Zhonghua Wai Ke Za Zhi 2010, 48:450–453.PubMed 21. Hori M, Furusato M, Nikaidoh T, Aizawa S: Immunohistochemical demonstration of cell proliferation and estrogen receptor status in human breast cancer. Analysis of 45 cases. Acta Pathol Jpn 1990, 40:902–907.PubMed 22. Bhargava V, Kell DL, van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145:535–540.PubMed 23. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994, 69:135–139.PubMedCrossRef 24. van Meerloo J, Kaspers GJ, Cloos J: Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011, 731:237–245.PubMedCrossRef 25. Chao DT, Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 1998, 16:395–419.PubMedCrossRef 26. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81:151–157.PubMed 27.